Teva Pharmaceutical Industries is back in focus after a fair value estimate was lifted from US$42.00 to US$45.30, a move that puts fresh attention on how analysts see the stock today. The higher target sits alongside recent commentary that stresses both confidence in Teva’s transformation and the need for tight execution across its neuropsychiatry and central nervous system portfolio. As you read on, you will see what is shaping this evolving narrative and how to keep track of the key...

Teva Pharmaceutical Industries is back in focus after a fair value estimate was lifted from US$42.00 to US$45.30, a move that puts fresh attention on how analysts see the stock today. The higher target sits alongside recent commentary that stresses both confidence in Teva’s transformation and the need for tight execution across its neuropsychiatry and central nervous system portfolio. As you read on, you will see what is shaping this evolving narrative and how to keep track of the key...

Samsung Bioepis deal puts Teva Pharmaceutical Industries in focus Teva Pharmaceutical Industries (NYSE:TEVA) has moved higher up investor watchlists after a new global agreement with Samsung Bioepis covering up to six biosimilar candidates, including respiratory and immunology assets. The fresh tie-up extends an existing relationship that already includes EPYSQLI in the U.S. and OPUVIZ in Canada. It also lands just days after FDA approval of DEGEVMA, adding another biosimilar pillar to Teva’s...

Teva Pharmaceutical Industries is scheduled to report Q3 2026 earnings on November 3, 2026. See the scheduled call time, analyst EPS and revenue estimates, and past results for TEVA at MarketBeat.

Layoffs at Teva Tech in Ramat Hovav are part of a global restructuring of TAPI, Teva’s active pharmaceutical ingredients unit, as the company weighs a possible sale

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Teva Pharmaceutical Industries stock was at USD 39.92 on October 5, while FDA approval added a secon

Las acciones de Teva Pharmaceutical Industries se situaron en 39,53 dólares el 2 de octubre de 2026, después de una caída del 0,56 por ciento.

The Royal College of Nursing canceled the Israeli drugmaker's sponsorship of an upcoming conference after pressure from pro-Palestinian groups

View the basic TEVA option chain and compare options of Teva Pharmaceutical Industries Limited on Yahoo Finance.

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs despite volatility from a Federal Reserve leadership transition and Middle East tensions. Markets rebounded from Q1 lows, […]